AU2020322072A1 - 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents - Google Patents

3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents Download PDF

Info

Publication number
AU2020322072A1
AU2020322072A1 AU2020322072A AU2020322072A AU2020322072A1 AU 2020322072 A1 AU2020322072 A1 AU 2020322072A1 AU 2020322072 A AU2020322072 A AU 2020322072A AU 2020322072 A AU2020322072 A AU 2020322072A AU 2020322072 A1 AU2020322072 A1 AU 2020322072A1
Authority
AU
Australia
Prior art keywords
methyl
amino
propyl
mmol
thiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020322072A
Other languages
English (en)
Inventor
Simon Bedford
Maïa CHANRION
Frédéric COLLAND
James Edward Paul Davidson
Patrice Desos
Mark Philip DODSWORTH
Petra Dunkel
András HERNER
András Kotschy
Zoltán MADARÁSZ
Ana Leticia MARAGNO
Márk MOLNÁR
James Brooke MURRAY
Tibor NOVÁK
Miklós NYERGES
Attila Paczal
Rachel Jane PARSONS
Monika RUDASOVÁ
Jérôme-Benoît STARCK
Ágnes STROFEK
Marianna SZIGETI
Mátyás Pál TIMÁRI
Paul Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Vernalis R&D Ltd
Original Assignee
Les Laboratoires Servier SAS
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS, Vernalis R&D Ltd filed Critical Les Laboratoires Servier SAS
Publication of AU2020322072A1 publication Critical patent/AU2020322072A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020322072A 2019-07-29 2020-07-28 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents Pending AU2020322072A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19188747.0 2019-07-29
EP19188747 2019-07-29
PCT/EP2020/071179 WO2021018857A1 (en) 2019-07-29 2020-07-28 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents

Publications (1)

Publication Number Publication Date
AU2020322072A1 true AU2020322072A1 (en) 2022-02-10

Family

ID=67514281

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020322072A Pending AU2020322072A1 (en) 2019-07-29 2020-07-28 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents

Country Status (24)

Country Link
US (1) US20220289734A1 (https=)
EP (1) EP4003988A1 (https=)
JP (1) JP7646626B2 (https=)
KR (1) KR20220042182A (https=)
CN (1) CN114450283B (https=)
AR (1) AR119493A1 (https=)
AU (1) AU2020322072A1 (https=)
BR (1) BR112022001330A2 (https=)
CA (1) CA3148502A1 (https=)
CL (1) CL2021003594A1 (https=)
CO (1) CO2022000700A2 (https=)
CR (1) CR20220014A (https=)
DO (1) DOP2022000015A (https=)
GE (2) GEAP202415866A (https=)
IL (1) IL289932B2 (https=)
JO (1) JOP20220006A1 (https=)
MX (1) MX2022001161A (https=)
PE (1) PE20220704A1 (https=)
PH (1) PH12022550018A1 (https=)
PY (1) PY2039849A (https=)
SA (1) SA522431498B1 (https=)
TW (1) TWI900486B (https=)
UY (1) UY38809A (https=)
WO (1) WO2021018857A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021386367A1 (en) * 2020-11-24 2023-06-22 Les Laboratoires Servier Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
JP2024505562A (ja) * 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
CN119562832A (zh) 2022-05-20 2025-03-04 诺华股份有限公司 Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
AU2023271885A1 (en) 2022-05-20 2024-12-12 Les Laboratoires Servier Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
US20250387504A1 (en) 2022-05-20 2025-12-25 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059354A2 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
EA201001030A1 (ru) * 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SG11201709837RA (en) * 2015-05-29 2017-12-28 Teijin Pharma Ltd PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Also Published As

Publication number Publication date
EP4003988A1 (en) 2022-06-01
KR20220042182A (ko) 2022-04-04
CR20220014A (es) 2022-03-02
SA522431498B1 (ar) 2025-04-13
TW202118761A (zh) 2021-05-16
CL2021003594A1 (es) 2022-11-18
US20220289734A1 (en) 2022-09-15
DOP2022000015A (es) 2022-05-15
WO2021018857A1 (en) 2021-02-04
BR112022001330A2 (pt) 2022-05-17
JP2022542937A (ja) 2022-10-07
UY38809A (es) 2021-02-26
IL289932A (en) 2022-03-01
CA3148502A1 (en) 2021-02-04
CO2022000700A2 (es) 2022-02-07
MX2022001161A (es) 2022-02-22
IL289932B1 (en) 2025-10-01
CN114450283A (zh) 2022-05-06
GEP20247670B (en) 2024-09-25
JOP20220006A1 (ar) 2023-01-30
GEAP202415866A (en) 2024-06-10
NZ784583A (en) 2025-02-28
IL289932B2 (en) 2026-02-01
PE20220704A1 (es) 2022-05-04
PY2039849A (es) 2021-05-06
PH12022550018A1 (en) 2022-10-17
CN114450283B (zh) 2024-05-07
TWI900486B (zh) 2025-10-11
AR119493A1 (es) 2021-12-22
JP7646626B2 (ja) 2025-03-17

Similar Documents

Publication Publication Date Title
JP7805283B2 (ja) ガンを処置するためのｂｃｌ－ｘｌタンパク質阻害剤及びアポトーシス促進剤としての、６，７－ジヒドロ－５ｈ－ピリド［２，３－ｃ］ピリダジン誘導体及び関連化合物。
JP7646626B2 (ja) ３，６－ジアミノ－ピリダジン－３－イル誘導体、それを含有する医薬組成物及びアポトーシス促進剤としてのその使用
KR102030609B1 (ko) Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
JP6206926B2 (ja) 異常なプロテインキナーゼｃのチエノピリミジン阻害剤
US20240374606A1 (en) Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
RU2830186C2 (ru) 3,6-диаминопиридазин-3-ильные производные, содержащие их фармацевтические композиции и их применение в качестве проапоптотических средств
OA20487A (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents.
RU2832191C2 (ru) 6,7-дигидро-5h-пиридо[2,3-c]пиридазиновые производные и родственные соединения в качестве ингибиторов белков bclxl и проапоптотических средств для лечения злокачественных новообразований
EA046336B1 (ru) 3,6-диаминопиридазин-3-ильные производные, содержащие их фармацевтические композиции и их применение в качестве проапоптотических средств
HK40068269A (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
EA052683B1 (ru) 6,7-ДИГИДРО-5H-ПИРИДО[2,3-c]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BCL-XL И ПРОАПОПТОТИЧЕСКИХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
HK40074798A (en) 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer
HK40068269B (zh) 3，6-二氨基-哒嗪-3-基衍生物、含有它们的药物组合物及其作为促凋亡剂的用途